Biotech of the Week: Agios Pharmaceuticals

As part of their weekly show, Biotech Banter, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso occasionally run a segment highlighting a biotech. This week's honor goes to Agios Pharmaceuticals , which IPOed last year.

The company zoomed up 28% on Monday after presenting positive data on its cancer drug AG-221 at the American Association for Cancer Research over the weekend. In a small Phase 1 trial, six of seven evaluable patients with acute myeloid leukemia responded to AG-221, including three complete remissions and two complete remissions with incomplete platelet recovery. That's pretty amazing, considering these patients had already failed previous treatments.

Agios' pipeline is in the relatively early stages, with a couple of products, including AG-221, licensed to Celgene . To justify its $1.4 billion market cap, the drugs will have to work in later-stage trials, but so far everything looks promising.

Watch the following video for Brian's and Max's takes on Agios Pharmaceuticals.

3 stocks poised to be multibaggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multibagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

The article Biotech of the Week: Agios Pharmaceuticals originally appeared on

Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story